DIALYSIS-TIR Study

NCT06042153 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing how a treatment affects time-in-range (70-180 mg/dl) blood sugar levels in adults with type 2 diabetes who are on dialysis for end-stage kidney disease.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 43 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-12 · est. completion 2028-09

Where 5 sites · United States

What this study is testing ClinicalTrials.gov NCT06042153 ↗

Description as written by the study sponsor.

This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly. Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 days at five different time points during the study.

Treatments tested

Semaglutide Drug

Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.25 mg; dose will gradually be increased every 4 weeks up to 1.0 mg.
Placebo Drug

Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.

Main thing measured	Change in TIR (70-180 mg/dl)
Sponsor	University of Texas Southwestern Medical Center
Conditions studied	Type 2 Diabetes, End Stage Renal Disease on Dialysis
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06042153 ↗